About: Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $107.04 (-1.92%)
DNTHNASDAQDianthus Therapeutics Inc.
Dianthus Therapeutics Inc. share price
DNTH price activity
Último preço
$ 107,040
Variação (24h)
-2,09 USD (-1,92%)
Volume
686.71K
Volume (média 4 sem.)
-
Abertura
$ 108,03
Variação do dia
$ 106,00 - $ 110,19
Fechamento anterior
$ 109,13
Último negócio
09 Sep, 8:00 pm GMT+0
Atrasado
09 Sep, 8:00 pm GMT+0
DNTH price performance
Atrasado
09 Sep, 8:00 pm GMT+0
quote.marketSignals